



## KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 02, 2025

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--Jul. 2, 2025-- KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the compensation committee of KalVista's board of directors granted five newly-hired employees inducement options to purchase an aggregate of 23,000 shares of KalVista common stock on July 1, 2025 as inducements material to each employee entering into employment with KalVista. The options have an exercise price that is equal to the closing price of KalVista common stock on the grant date.

One-fourth of the options vest on the one-year anniversary of the vesting commencement date and the remainder vest in equal monthly installments over the next three years, in each case subject to the new employee's continued service with the company. Each stock option has a 10-year term and is subject to the terms and conditions of KalVista's Inducement Equity Incentive Plan and a stock option agreement covering the grant.

The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

### About KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc., is a global biopharmaceutical company dedicated to developing and delivering life-changing oral therapies for individuals affected by rare diseases with significant unmet needs. Our lead investigational product is sebetralstat, a novel, oral, on-demand treatment for hereditary angioedema (HAE). Sebetralstat is under regulatory review by the U.S. FDA. In addition, we have completed Marketing Authorization Applications for sebetralstat to the European Medicines Agency and multiple other global regulatory authorities.

For more information about KalVista, please visit [www.kalvista.com](http://www.kalvista.com) or follow on social media at [@KalVista](https://twitter.com/KalVista) and [LinkedIn](https://www.linkedin.com/company/kalvista).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20250702705900/en/): <https://www.businesswire.com/news/home/20250702705900/en/>

### KalVista Pharmaceuticals, Inc.

#### Investors:

Ryan Baker  
Head, Investor Relations  
(617) 771-5001  
[ryan.baker@kalvista.com](mailto:ryan.baker@kalvista.com)

#### Media:

Molly Cameron  
Director, Corporate Communications  
(857) 356-0164  
[molly.cameron@kalvista.com](mailto:molly.cameron@kalvista.com)

Source: KalVista Pharmaceuticals, Inc.